Texas Roadhouse earnings missed by $0.05, revenue topped estimates
Solomon Moshkevich, President, Clinical Diagnostics at Natera, Inc. (NASDAQ:NTRA), a $19.2 billion market cap company, sold 3,000 shares of common stock on August 1, 2025, according to a Form 4 filing with the Securities and Exchange Commission. According to InvestingPro data, the company maintains a "GOOD" financial health score, with analysts maintaining a strong buy consensus. The sales were executed in multiple transactions at prices ranging from $132.4528 to $134.08, netting Moshkevich approximately $398657 from the transactions.
The filing indicates that 1,574 shares were sold at a weighted average price of $132.4528, 1,326 shares were sold at a weighted average price of $133.3097 and 100 were sold at $134.08.
Following the reported transactions, Moshkevich directly owns 123,059 shares of Natera, Inc.
The stock sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Moshkevich on November 26, 2024.
In other recent news, Natera has made significant strides with its financial and product developments. The company reported strong first-quarter results for 2025, prompting RBC Capital Markets to maintain an Outperform rating and a price target of $251, citing accelerated revenue growth and effective commercial execution as key factors. Additionally, TD Cowen raised its price target for Natera to $200, acknowledging a 13% increase in sales driven by a 5% rise in core sales and other favorable developments. Natera’s Signatera product saw substantial growth, with clinical volumes rising to approximately 17,000 in the first quarter, a 52% year-over-year increase.
The company also received positive news regarding Medicare coverage. Medicare expanded its coverage for Natera’s Signatera MRD assay to include various cancers, following a study presented at the 2025 American Society of Clinical Oncology Annual Meeting. This expansion is expected to enhance the assay’s clinical utility and market reach. Furthermore, Evercore ISI initiated coverage on Natera with an Outperform rating and a price target of $170, indicating optimism about the company’s market position.
Leerink Partners reiterated its Outperform rating for Natera, with a price target of $220, following developments in Medicare coverage for the WGS Signatera assay. This coverage decision was made after a bridging study demonstrated comparable performance between WGS Signatera and WES Signatera. These developments collectively highlight Natera’s strong position in the market and its ongoing efforts to expand its product offerings and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.